Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Purchased by Acadian Asset Management LLC

Acadian Asset Management LLC raised its position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 22.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 212,296 shares of the company’s stock after buying an additional 39,413 shares during the period. Acadian Asset Management LLC owned approximately 0.49% of Werewolf Therapeutics worth $516,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of HOWL. Janus Henderson Group PLC purchased a new position in Werewolf Therapeutics in the first quarter valued at about $10,922,000. Lighthouse Investment Partners LLC purchased a new position in shares of Werewolf Therapeutics during the 4th quarter valued at approximately $87,000. Vanguard Group Inc. grew its position in shares of Werewolf Therapeutics by 26.8% during the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after buying an additional 233,909 shares in the last quarter. Denali Advisors LLC bought a new stake in shares of Werewolf Therapeutics in the first quarter worth $172,000. Finally, PFM Health Sciences LP raised its holdings in Werewolf Therapeutics by 35.6% in the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after acquiring an additional 909,895 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on HOWL. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, July 2nd. Wedbush reiterated an “outperform” rating and issued a $9.00 price target on shares of Werewolf Therapeutics in a research note on Monday, June 3rd. Finally, JMP Securities restated a “market outperform” rating and set a $12.00 price objective on shares of Werewolf Therapeutics in a research note on Wednesday, June 26th.

Werewolf Therapeutics Stock Down 0.4 %

HOWL stock opened at $2.22 on Thursday. The firm has a fifty day moving average price of $2.31 and a two-hundred day moving average price of $3.99. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.13 and a quick ratio of 12.13. Werewolf Therapeutics, Inc. has a 1-year low of $1.57 and a 1-year high of $8.19. The firm has a market cap of $96.47 million, a price-to-earnings ratio of -2.04 and a beta of 0.46.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. The business had revenue of $1.14 million for the quarter, compared to analyst estimates of $2.00 million. Research analysts predict that Werewolf Therapeutics, Inc. will post -1.64 EPS for the current year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.